On June 4, Abivax S.A. rose 5.65% in regular trading, trading at $98.5/share, with trading volume of $127 million. The stock continues to rebound after plunging over 40% earlier this week.

The recovery follows a sharp selloff triggered by the company's Phase 3 maintenance trial results for obefazimod in moderately to severely active ulcerative colitis. While the trial met its primary endpoint — with clinical remission rates of 50.8% (25 mg) and 51.3% (50 mg) versus 10.4% for placebo — three malignancy cases in the 50 mg group (prostate cancer, breast cancer, and colonic dysplasia) sparked severe market concern. The stock was halted on Nasdaq before results were disclosed and crashed upon resumption.

Jefferies analysts noted that cancer-related adverse events will continue to weigh on sentiment and the drug's commercialization outlook regardless of causality. Wedbush Securities flagged an increasing risk of a black box warning. The current rebound reflects some bargain-hunting activity, though safety concerns remain unresolved.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)